1
Inpharma 1224 - 12 Feb 2000 Interferon (IFN)-β-1a delays the onset of clinically definite multiple sclerosis (MS) in patients who have experienced the recent onset of a first demyelinating event, report researchers from the CHAMPS * study. 383 such patients were randomised to receive IM IFN- β-1a [‘Avonex’] 30µg or placebo, once weekly for 3 years. Results of an interim analysis conducted by the independent Data Monitoring Committee reveal that IFN-β-1a, compared with placebo, recipients had a significantly delayed onset of clinically definite MS, exceeding the pre-established criteria required for early termination of the trial. Consequently, the trial will stop early. * Controlled High Risk Subjects Avonex® Multiple Sclerosis Prevention Study Biogen Inc. Biogen’s AVONEX (Rm) (interferon beta-1a) shows a beneficial effect on delaying the development of multiple sclerosis. Data Monitoring Committee recommends stopping CHAMPS Trial early; Biogen to apply for broadened label with regulatory authorities. Media Release : [2 pages], 1 Feb 2000. Available from: URL: http://www.biogen.com 800801706 1 Inpharma 12 Feb 2000 No. 1224 1173-8324/10/1224-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Interferon (IFN)-β-1a delays the onset of clinically definite multiple sclerosis

  • View
    212

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Interferon (IFN)-β-1a delays the onset of clinically definite multiple sclerosis

Inpharma 1224 - 12 Feb 2000

■ Interferon (IFN)-β-1a delays the onset of clinicallydefinite multiple sclerosis (MS) in patients who haveexperienced the recent onset of a first demyelinatingevent, report researchers from the CHAMPS* study.383 such patients were randomised to receive IM IFN-β-1a [‘Avonex’] 30µg or placebo, once weekly for ≤ 3years. Results of an interim analysis conducted by theindependent Data Monitoring Committee reveal thatIFN-β-1a, compared with placebo, recipients had asignificantly delayed onset of clinically definite MS,exceeding the pre-established criteria required forearly termination of the trial. Consequently, the trialwill stop early.* Controlled High Risk Subjects Avonex® Multiple SclerosisPrevention Study

Biogen Inc. Biogen’s AVONEX (Rm) (interferon beta-1a) shows a beneficialeffect on delaying the development of multiple sclerosis. Data MonitoringCommittee recommends stopping CHAMPS Trial early; Biogen to apply forbroadened label with regulatory authorities. Media Release : [2 pages], 1 Feb2000. Available from: URL: http://www.biogen.com 800801706

1

Inpharma 12 Feb 2000 No. 12241173-8324/10/1224-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved